Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

@inproceedings{Bernal2021EffectivenessOC,
  title={Effectiveness of COVID-19 vaccines against the B.1.617.2 variant},
  author={Jamie Lopez Bernal and Nick Andrews and Charlotte M. Gower and Eileen Gallagher and Ruth Simmons and Simon Thelwall and Julia Stowe and Elise Tessier and Natalie Groves and Gavin Dabrera and Richard Myers and Colin N J Campbell and Gayatri Amirthalingam and Matt Edmunds and Maria Zambon and Kevin E Brown and Susan Hopkins and Meera Chand and Mary E Ramsay},
  booktitle={medRxiv},
  year={2021}
}
Background: The B.1.617.2 COVID-19 variant has contributed to the surge in cases in India and has now been detected across the globe, including a notable increase in cases in the UK. We estimate the effectiveness of the BNT162b2 and ChAdOx1 COVID-19 vaccines against this variant. Methods: A test negative case control design was used to estimate the effectiveness of vaccination against symptomatic disease with both variants over the period that B.1.617.2 began circulating with cases identified… 
Effectiveness of COVID-19 vaccines against variants of concern, Canada
TLDR
The findings suggest that even a single dose of these 3 vaccine products provide good to excellent protection against symptomatic infection and severe outcomes caused by the 4 currently circulating variants of concern, and that 2 doses are likely to provide even higher protection.
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
TLDR
This study suggests that two dose regimes of vaccine are required for maximal BNT162b2 and ChAdOx1-induced immunity and demonstrates the quantifiable risk of antigenic drift and subsequent reduction in vaccine efficacy.
Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
TLDR
There was a lower incidence of infection with SARS-CoV-2 due to Delta variant was found after the second dose of Pfizer-BioNTech, Oxford-AstraZeneca and Moderna vaccines, and in fully vaccinated individuals, symptomatic infection with the delta variant was significantly reduced, and therefore, vaccinations play an important role to assist the fight against delta variant.
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
TLDR
Evidence suggests that T-cell responses are preserved across vaccine platforms, regardless of variant of concern, which suggests the potential for reduced efficacy or effectiveness against current and future SARS-CoV-2 variants is low.
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
TLDR
The susceptibility of these newly emerged variants to BNT162b2 vaccine-elicited neutralization supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic across geographies.
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
TLDR
Infectious SARS-CoV-2 B.1.617.2 spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes, which is believed to spread faster than the other versions.
Progress of the Delta variant and erosion of vaccine effectiveness, a warning from Utah
TLDR
A modest reduction in vaccine effectiveness against COVID-19 in Utah corresponding to the expansion of the Delta lineage in the state is shown, which is highly concerning.
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
TLDR
Compared with the Alpha variant, VE against mild outcomes was reduced by 10–20%, but fully maintained against severe COVID-19, which has become the dominant strain of SARS-CoV-2.
Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients
TLDR
The reduction in antibody titers against the viral variants that emerged in the United Kingdom, Brazil, and South Africa suggests that previous symptomatic infection might be not fully protective against exposure to SARS-CoV-2 variants carrying a set of relevant spike mutations.
SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough
TLDR
In an analysis of over 130 SARS-CoV-2 infected healthcare workers across three centres in India during a period of mixed lineage circulation, substantially reduced ChAdOx-1 vaccine efficacy against B.617.1.2 Delta variant warrants continued infection control measures in the post-vaccination era.
...
...

References

SHOWING 1-10 OF 33 REFERENCES
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
TLDR
The recent emergence of new SARS-CoV-2 variants B.1.2.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
TLDR
The recent emergence of new SARS-CoV-2 variants B.2.1.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
TLDR
A two-dose regimen of NVX-CoV2373 conferred 89.7% protection against a blend of prototype and variant Covid-19, demonstrated high efficacy against the B.1.7 variant, and had a reassuring safety profile.
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
TLDR
This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People
TLDR
A single dose of the BNT162b2 mRNA and ChAdOx1 vaccines resulted in substantial reductions in the risk of COVID-19 related hospitalisation in Scotland.
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study)
TLDR
The first dose of BNT162b2 and ChAdOx1 vaccines was associated with substantially reduced SARS-CoV-2 infection risk in LTCF residents from 4 weeks to at least 7 weeks.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified.
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
TLDR
Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease.
...
...